A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting ...

Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseas ...

SK Biopharmaceuticals has added a second preclinical Parkinson’s disease therapy to its pipeline courtesy of a $314.8 million biobucks deal with a fellow South Korean drug developer. The deal centers ...

North Immunology has decided its path to taking its atopic dermatitis (AD) drug into the clinic involves going public via a ...

Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 biobucks pact with ...

Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis (ALS) program after flunking a phase 2 ...

Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead Sciences’ CEO ...

Sling Therapeutics has closed a $123 million series C round to advance its oral therapy for thyroid eye disease (TED) through a phase 3 trial and hopefully on to commercialization. | Sling ...

After teasing a new initiative to speed up early-stage clinical trials over the summer, the FDA today opened a pilot program ...

Jaguar LAA, a newly formed medtech, has acquired assets that are part of Johnson & Johnson’s Afib device Laminar program for an undisclosed price. The Laminar device focuses on a catheter-based left ...

Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a ...

Eli Lilly’s ongoing attempt to strengthen its genetic medicine offering has seen the company pledge up to $237 million in ...